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Abstract
In recent years, a precision medicine approach, which customizes medical treatments based on patients’ individual profiles and
incorporates variability in genes, the environment, and lifestyle, has transformed medical care in numerous medical fields, most
notably oncology. Applying a similar approach to Parkinson’s disease (PD) may promote the development of disease-modifying
agents that could help slow progression or possibly even avert disease development in a subset of at-risk individuals. The urgent
need for such trials partially stems from the negative results of clinical trials where interventions treat all PD patients as a single
homogenous group. Here, we review the current obstacles towards the development of precision interventions in PD. We also
review and discuss the clinical trials that target genetic forms of PD, i.e., GBA-associated and LRRK2-associated PD.
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Parkinson’s disease (PD) is the second most common neuro-
degenerative disorder, affecting more than 6 million people
worldwide [1]. Numerous drugs for the treatment of motor
and non-motor symptoms of PD are available on the market.
While these drugs improve motor symptoms and quality of
life of people with PD, there is no evidence that any of these
interventions modify the progression of PD pathology. There
are no FDA-approved interventions to slow down PD progres-
sion even though there have been multiple clinical trials for
treatments that would modify the PD pathophysiological pro-
cess. One potential explanation of this challenge is that PD is
not a single patho-biological process. Consequentially, a tai-
lored approach, where interventions are selected by the pa-
tients’ genotype or other biomarkers (as a measure of a bio-
logical process associated with a disease state), is required. In
parallel, our knowledge of genetic risks has expanded
significantly in the past decade and makes a precision medi-
cine approach in PD very timely. Here, we review the obsta-
cles towards the completion of clinical trials in PD along with
the efforts to overcome these challenges. We outline the cur-
rently available data on precision medicine clinical trials, fo-
cu s i ng p r ima r i l y on a lpha synuc l e i n (SNCA ) ,
glucocerebrosidase (GBA), and Leucine-Rich Repeat Kinase
2 (LRRK2).
Precision Medicine
Precision medicine aims to tailor treatment in a personalized
manner, for the right person at the right time. To achieve this,
it uses diagnostic tools to identify specific biomarkers, often
genetic, to help assess which medical treatments will be best
for each patient [2]. Thus, in addition to the mission of pro-
viding personalized medicine, the term precision medicine
also conveys the concept that genomics and other emerging
biodata sciences will improve medicine’s clinically defined
nosology [3].
The hypothesis underlying precision medicine is that dis-
eases previously treated as a single condition are actually bi-
ologically different, and that treatment should be tailored
based on the biological signature of the individual (stratified
medicine [3]). A successful example is oncology, where
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precision medicine led to the identification of effective thera-
pies based on tumor profiling and a better understanding of
how tumors become resistant to cancer therapy (https://www.
cancer.gov/research/areas/treatment/pmi-oncology). In PD,
precision trials are ongoing for genetic forms of PD.
Genetic Underpinnings of Parkinson’s Disease
In recent years, our understanding of the genetics of PD has
expanded significantly. In addition to over a dozen Mendelian
loci (Fig. 1), multiple PD genetic risk factors have been iden-
tified. These risk factors are mostly associated with a small
increase in risk of PD (e.g. up to ~1.5-fold) but occur as com-
monly as 40% in the general population [5]. It is thought that
the overall heritable component of disease is about 30% (5–
10% due to monogenic causes and around 22% driven by
common variants identified by genome-wide association stud-
ies) [6–8]. A prevailing hypothesis is that many of the identi-
fied genes and risk factors map into two closely related and
overlapping cellular pathways: mitochondrial metabolism and
autophagy. In addition, other pathways such as endosomal
trafficking, synaptic transmission and immune response path-
ways have been identified to play a role in the pathogenesis of
PD. [7, 9] While these biological pathways have been linked
to PD via genetic studies, it is very likely that dysfunction in
these same pathways due to environmental exposures could
also lead to PD. Figure 1 describes the genetic architecture of
PD.
The genetic risks for PD can be roughly divided into three
groups, based on their frequency in the general population and
the PD risk they convey. Accordingly, clinical trial designs for
each one of these groups may also differ.
1 Group A includes most of the Mendelian genes linked to
PD (shown in the left upper part of Fig. 1). These muta-
tions convey a major risk factor for PD, but are extremely
rare. In most cases, mutations are present in too few pa-
tients for a standard clinical trial design (e.g., PINK1 or
PARK7). Intervention on such mutations would require a
Fig. 1 Genetic architecture of Parkinson’s disease, modified from [4] and
[5], showing the continuum of variants of different effect strengths and
allele frequencies. The size of the bubbles roughly corresponds to
population allele frequencies. Colors symbolize modes of inheritance:
dominant (red), recessive (yellow), risk loci (green). The genetic risks
for PD can be roughly divided into three groups (dotted areas; see main
text for more details). The group of common low-risk genes (lower right
corner) includes more than 90 putative independent genome-wide signif-
icant signals identified in a GWAS meta-analysis based on more than
13,000 patients and 95,000 controls [6]. Similar to LRRK2 and SNCA,
some mutations in VPS13C and GCH1 are likely causal or confer high
risk for PD [6]
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different study design such as patient-customized therapy.
A recent report of patient-customized intervention in a
child with neuronal ceroid lipofuscinosis 7 (CLN7, a form
of Batten’s disease) demonstrates the potential of this type
of study [10]. Among all of these rare PD mutations, mu-
tations in SNCA and Parkin may be more common.
Indeed, if a sufficient amount of SNCA mutation carriers
are identified, there may be promising interventions in this
patient population group including silencers of the SNCA
gene (e.g., antisense oligonucleotides (ASOs), viral-
mediated delivery of siRNA, and miRNA. Of these,
ASOs have recently shown favorable results in patients
with spinal muscular atrophy [11] and Huntington’s dis-
ease [12]. As described below, these treatments may also
be useful for a broader range of PD patients.
2 Group C includes variants which convey a very low in-
creased risk for PD (shown in green on the right in Fig. 1),
but may be present in a large percentage of people with
PD. These variants may be common enough that interven-
tion on the biological pathway of one of these variants may
not require pre-screening clinical trial candidates, but in-
stead result in stratifying the participants based on the
presence of the variant. For example, a major pathway
highlighted by GWAS analysis in large PD cohorts is the
adaptive immune system. This was first identified through
a human leukocyte antigen association but is now increas-
ingly recognized as a major determinant of risk across the
genome [13]. We are not aware of any current clinical
trials that focus on a Group C gene for PD. However,
ASOs (developed by Ionis) targeting tau (MAPT) are being
studied in a phase I clinical trial for Alzheimer’s disease. In
addition, retroactive analyses of published clinical trials
may identify responders versus non-responders based on
variant status. It is possible that unsuccessful clinical trials
for disease-modifying agents would have been successful
in a select group of people with PD.
3 Group B includes variants that are shown in the middle of
Fig. 1. They are deleterious enough (associated with a high
enough risk for PD) to warrant an intervention, but also
common enough to make clinical trials targeting mutation
carriers with a reasonably high number of participants fea-
sible. Currently, this group includes variants in GBA and
LRRK2. Given tremendous efforts to identify research co-
horts, (e.g., by the Michael J. Fox Foundation-funded
PPMI studies) our knowledge of the PD phenotype and
the risk for PD among these mutation carriers has im-
proved [14, 15].
The differences among the groups (A/B/C) are derived
from the frequency of the variant in the population (x-axis),
and the risk for PD associated with the variant (y-axis). The
relationship between frequency and PD risk can guide the
study design and who will benefit from particular
interventions. Specifically, mutations in group A are rare,
and interventions on these targets may not benefit all PD
cases. One example of this is homozygous carriers of PRKN
mutations. We are not aware of such studies in group A in PD
but an example from the dementia field would be for intra-
cisternal PR006 administration of the progranulin protein
(PGRN) in carriers of the progranulin gene mutation (https://
clinicaltrials.ucsf.edu/trial/NCT04408625). This type of
intervention would not be for all patients with dementia but
would only include mutation carriers. The study design would
have to include genotype as an inclusion criterion and a large
number of PD cases would have to be genotyped to identify a
small number of participants. Variants in group C are common
and intervention on them may be beneficial for all PD cases.
An example would be interventions on alpha-synuclein (α-
syn) in PD. These studies do not require prescreening for
genetic variants prior to study participation.
Current Research and Clinical Trials
for Genetic Forms of PD
SNCA-Associated Parkinsonism: Active and Passive
Immunization
Discovered in 1997, SNCA, which encodes the protein prod-
uct α-syn, was the first cloned gene for PD. Soon after, it was
discovered that α-syn is a key component of Lewy bodies
which are considered to be a pathological hallmark of PD.
Therefore, the link between α-syn and PD seems clear and
extends beyond the genetic cases caused by SNCAmutations.
The physiological state of α-syn is an intrinsically disordered
monomer or helically folded tetramere that has toxic effects in
its oligomeric form. The protein is degraded mainly by the
autophagic system. Pathogenic missense mutations (A53T
[16], A30P [17], E46K [18] and H50Q [19] and G51D [20]
[PARK1] which leads to misfolding and promotes apoptosis)
and changes in gene dosage (duplications, triplications
[PARK4] which leads to an excess and aggregation of α-
syn) are associated with PD (Fig. 2). The prevailing hypothe-
sis is that excess α-syn is pathogenic and that mutations in the
SNCA gene lead to gain-of-function. Indeed, the clinical phe-
notype of mutation carriers has been associated with early-
onset rapid motor progression and frequent dementia; the phe-
notype may also overlap with multiple system atrophy (MSA)
or dementia with Lewy bodies (DLB). Following the dosage
effect, the disease may be more rapidly progressive in tripli-
cation carriers versus duplication carriers.
Multiple clinical trials are targeting alpha-synuclein. While
SNCA mutation carriers would naturally benefit from such
interventions, given the difficulty recruiting large enough co-
horts of these carriers, none of the trials focuses solely on this
population. Sinceα-syn deposits are universally present in PD
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andMSA, the trials include both PD andMSA patients. While
a very attractive drug target, one of the challenges of the field
is that there are no α-syn tracers available. Developing α-syn
tracers would help advance the field as they may serve as
biomarkers, specifically for target engagement.
Multiple mechanisms of actions are currently being studied
for α-syn, including immunotherapies, gene therapies, and
small molecules (Table 1).
Immunotherapies
Immunotherapies include active immunization (i.e., a vacci-
nation which triggers the immune system to generate an im-
mune reaction, including antibodies, against α-syn), and pas-
sive immunization (i.e., administration of antibodies directed
against different domains of α-syn). Since it is estimated that
antibodies would be most effective against extracellular pro-
teins, these immunotherapies are designed to reduce the load
of extracellular α-syn, stop the spread of α-syn pathology in
the brain, and/or neutralize its toxic effects. While active vac-
cinations are generally associated with a higher potential risk
of side effects, so far no relevant safety and tolerability issues
have occurred in the current α-syn studies. However, active
vaccination strategies (such as AFFITOPE) have only been
tested in phase 1 human trials.
Of the passive vaccinations, two compounds have reached
the clinical phase 2 study level and are currently tested in
patients with early PD: PRX002 (PASADENA study, spon-
sored by Prothena) and BIIB054 (SPARK study, sponsored
by Biogen). The first antibody, prasinezumab (PRX002/
RO7046015), binds to the C-terminus of α-syn. A study in
healthy volunteers [22] and in mild-to-moderate PD patients
[23] demonstrated a favorable safety and tolerability profile
which led to the international PASADENA study. A total of
68 centers in the USA and Europe (i.e., Austria France,
Germany, and Spain) participate in this 52-week trial.
Completion is estimated for early 2021.
The second α-syn antibody, BIIB054, binds to the N-
terminus of α-syn, to residues 1–10 [24]. BIIB054 is highly
selective for aggregated forms of α-syn with at least an 800-
fold higher apparent affinity for fibrillar versus monomeric
recombinant α-syn and it has a strong preference for human
PD brain tissue. Efficacy studies in three different mouse
models with intracerebrally inoculated preformed α-syn fi-
brils showed that BIIB054 treatment attenuated the spreading
of α-syn pathology, rescued motor impairment, and reduced
the loss of dopamine transporter density in dopaminergic ter-
minals in the striatum. This led Biogen to initiate the interna-
tional SPARK study which consists of monthly IV infusions
(at 250 mg, 1250 mg, or 3500 mg) over 52 weeks. Another
Fig. 2 World map of SNCA-associated Parkinsonism. A total of 140 cases have been reported in the literature. Circles reflect frequency per region. Data
and image were retrieved from the MDSGene Website [21]
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compound in the pipeline for passive immunization is
MEDI1341 [25] (phase 1).
Small Molecules
Another approach that takes a different route of action is small
molecules which penetrate the blood–brain barrier and modify
α-syn biology. These include inhibition of α-syn misfolding
and aggregation and reduction of cortical pathology
(NPT200-11 [26], currently in phase 1). Another small mole-
cule mechanism utilized is targeting misfolded or aggregated
proteins (NPT088, a second-generation immunoglobulin-gen-
eral amyloid interaction motif (Ig-GAIM) molecule, which is
being developed by the company Neurophage). In the case of
anα-syn overexpression-based PD rat model, VH14*PEST (a
nanobody which targets the non-amyloid component region)
showedmaintenance of striatal dopaminergic tone andmodest
behavioral improvement [27]. Nanobodies are genetically
engineered fragments of antibodies which can modulate mo-
nomeric concentrations of target proteins.
Gene Therapy
Another potential strategy is gene therapy, namely the
CRISPR-dCas9 epigenome-editing approach which ma-
nipulates endogenous SNCA levels. Researchers at Duke
Un ive r s i t y ( now fu r t he r deve loped by See l o s
Therapeutics) designed an all-in-one lentiviral which har-
bors gRNA, dCas9 nuclease, and the catalytic domain
DNMT3A to target specific hypomethylated CpG islands
in the SNCA intron 1 region. This led to the downregula-
tion of SNCA mRNA and protein levels and phenotypic
perturbations in pluripotent stem cells of a SNCA triplica-
tion carrier [28].
Table 1 Compounds under development targeting alpha-synuclein
Mechanism of
action







PD01A, PD03A AFFITOPE Phase 1, completed 36 PD NCT02267434
Passive
immunization

































Anle138b [*] n/a Preclinical, a clinical trial in PD is




CLR01 [*] n/a Preclinical n/a
α-syn aggregation
inhibition
PBT434 [*] Alterity Therapeutics
Limited
Phase 1 70 MSA n.k.
α-syn aggregation
inhibition












Micro-RNA-101 [*] n/a Preclinical n/a
α-syn degradation
enhancers
TLR4-agonist MPLA [*] n/a Preclinical n/a







n/a = not applicable; n.k. = not known
*Compounds primarily being tested in MSA
†Trial completed in individuals with probable Alzheimer’s, may be applicable to synucleinopathies
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Given PD’s shared pathophysiological basis with MSA
(i.e., both are synucleinopathies), it will be interesting to fol-
low current developments in MSA as treatments may also be
effective in PD. α-syn aggregation inhibitors (e.g., Anle138b,
CLR01, PBT-434, and VX-765), passive immunization
(rec7), and α-syn degradation enhancers (e.g., rapamycin/
sirolimus) have been investigated for MSA; for a review, see
Heras-Garvin and Stefanova [29].
LRRK2-Associated Parkinsonism: Kinase Inhibitors Are
a Promising Target
More than 700 LRRK2 cases have been reported in the litera-
ture. The International LRRK2 Consortium study estimated
that the most common mutation in LRRK2, G2019S, accounts
for 1% of sporadic and 4% of familial PD patients [30].
Mutations in LRRK2 are more common in certain ethnicities.
North African Arabs (36% in familial, 39% in sporadic) and
Ashkenazi Jews (28% in familial, 10% in sporadic) have the
highest frequencies [30]. The G2019S mutation is common in
Whites, while G2385R and R1628P are the most frequent
variants in Asian patients (detected in around 5–10% of
Asian PD patients) [31]. Penetrance of LRRK2 is age depen-
dent and estimations in the general population are variable,
ranging between 30% and 74% [32]. There are multiple rea-
sons for this wide range of penetrance estimates, including
differences in study design, the investigation of different pop-
ulations, and the heterogeneity of LRRK2 presentation.
Regardless, the wide range of penetrance estimation makes
trial design for preventative interventions extremely difficult.
While the mechanisms by which LRRK2 mutations cause
PD have not been completely disentangled, there is increasing
evidence of increased LRRK2 kinase function in mutation
carriers with PD. The G2019S mutation, for example, results
in a direct two-to-threefold increase in kinase activity [33,
34].The potential gain-of-function effect is an attractive target
for treatment because inhibition is easier to achieve than im-
provement of reduced protein activity (as in GBA).
Furthermore, kinase inhibitors are widely used in oncology
and the PD field can benefit from advancements in other
fields. Since the first generation of LRRK2 inhibitors, newer
compounds have progressively improved in potency, selectiv-
ity, and brain penetrance. However, efficacy and safety remain
a concern. This is mainly due to the fact that other tissues,
particularly the kidney, lung, and a subtype of peripheral im-
mune cells, robustly express LRRK2. For example, the kidney
has a ~6.2-fold higher expression of LRRK2 compared to the
brain [34]. The expression of LRRK2 in other tissues is a
potential source of peripheral side effects, which can include
the development of lamelar bodies and impaired autophagy-
lysosomal function induced by LRRK2 inhibitors [35–37].
More recent data, however, suggest compounds that only par-
tially downregulate LRRK2 levels or kinase activity, i.e., by
50% or less, are unlikely to produce major side effects related
to on-target safety [38] and lipid droplets in lamelar bodies are
absorbed after the drug is stopped.
One alternative to avoid systemic toxicity is to find a
way to specifically modify LRRK2 activity in the brain
without modifying activity peripherally. New drug modal-
ities that keep peripheral side effects to a minimum include
PROTACs (PROeolysis TArgeting Chimera) which selec-
tively induce intracellular proteolysis via the ubiquitin–
proteasome system of the mutant without affecting WT-
LRRK2 [39]. However, due to their molecular size,
PROTACs show poor permeability across cell membranes
which might affect brain penetration [39]. Another alterna-
tive to avoid systemic side effects is currently tested by
Biogen, who launched a phase 1 antisense oligonucleotide
(ASO) trial. Participants will receive a single intrathecal
injection of the compound BIIB094, an ASO, on multiple
days. Recently, ASOs have been approved by the FDA for
spinal muscular atrophy and are being tested for
Huntington’s disease and non-neurological disorders such
as cancer [40, 41]. ASOs reduce the expression of a mu-
tated gene by binding to target mRNAs and either block
the translation of the abnormal protein or induce its degra-
dation [41]. ASOs can also promote splicing around muta-
tions. For disorders caused by toxic gain-of-function mu-
tations such as LRRK2, further investigation regarding
ASOs is warranted. In a preclinical study, administration
of LRRK2 ASOs to the brains of mice reduced LRRK2
protein levels and fibril-induced α-syn inclusions [42]; da-
ta from humans are not yet available.
Several structurally different LRRK2 inhibitors from
Genentech, GSK, Merck, and Pfizer are in the pipeline
(Table 2) [43]. The compounds developed by Denali are
already in clinical trials and a phase 1b trial in healthy
individuals has been completed which included pulmonary
and renal safety parameters. The company is advancing
DNL201 (GNE-7915) to a phase 1b safety and biomarker
study in LRRK2-linked PD and iPD (idiopathic PD).
Twenty-nine mild to moderately affected PD patients with
or without LRRK2 mutation were randomized to either low
dose DNL201, high dose DNL201, or placebo in this 28-
day randomized placebo-controlled trial. In January 2020,
Denali announced that both doses achieved more than 50%
inhibition of pS935 LRRK2 and pRab10 phosphorylation
in blood, and improved the lysosomal biomarker BMP in
urine (by 20% or 60% at the low and high dose) (https://
denalitherapeutics.gcs-web.com/node/7361/pdf [online]).
The same company also is testing another compound,
DNL151. In a trial in 150 healthy volunteers, safety and
biomarker goals were met (https://denalitherapeutics.gcs-
web.com/node/7361/pdf [online]). The compound is now
being tested in PD patients with recruitment in Belgium,
the Netherlands, and the UK; however, the trial is delayed
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because of the COVID-19 pandemic. According to the
press release, Denali intends to select either DNL201 or
DNL151 in mid-2020 to advance into phase 2/3 clinical
trials in patients with Parkinson’s disease (https://
denalitherapeutics.gcs-web.com/node/7361/pdf [online]).
To facilitate recruitment, a “direct-to-consumer” approach
for testing and counseling will be available [44]—a
strategy that proved successful in genetic testing with the
PPMI initiative. Most recently, Denali has announced a
strategic collaboration with Centogene, a gene diagnostic
lab, to enhance recruitment [45]. Pharmaceutical
companies and academic centers are also conducting
observational studies to identify best endpoints related to
the LRRK2 mutation, e.g. typical neurocognitive
abnormalit ies (https:/ /clinicaltrials.gov/ct2/show/
NCT01424475?term=lrrk2&draw=2&rank=8).
Deep Brain Stimulation for LRRK2-Associated PD
Interestingly, a different level of benefit was noted after deep
brain stimulation surgery in LRRK2-associated PD. The out-
come was better in patients with the most common LRRK2
mutation, p.G2019S, compared to the poor response seen in
patients with the rarer p.R1441G mutation. However, overall
numbers remain small. The overall benefit was compromised
by the rapid progression of cognitive and neuropsychiatric
symptoms [46].
Parkinsonism Associated with GBA Mutations
Clinical trials that target the glucocerebrosidase (GBA) path-
way are probably in the most advanced stages towards preci-
sion medicine in PD. This is a result of the relatively high
frequency of GBA mutations in PD and the availability of
basic science data collected about GBA mutations from
Gaucher disease research. GBA mutations are a common risk
factor for PD and are present in 7–10% of PD patients world-
wide. Among Ashkenazi Jews, around 20% of PD patients
carry a GBA mutation [47]. A high prevalence has also been
reported in the Netherlands, where 15.5% of PD patients carry
a GBA mutation [48].
HomozygousGBAmutations cause Gaucher disease (GD),
the most common autosomal recessive lysosomal storage dis-
ease, with an estimated annual incidence of 1/60,000 and an
estimated carrier frequency [49] of 0.7 to 0.8% in the general
population. The clinical presentation of GD can be divided
into systemic and neurological manifestations. The former,
present in all forms of GD, includes hepatosplenomegaly,
painful skeletal disorders, and pancytopenia. The latter is pres-
ent in the more severe types of GD, GD- type 2, and GD-type
3 [50]. More than 300 mutations in GBA have been reported
[51], and they are traditionally divided based on the GD phe-
notype they are associated with. Mild mutations (e.g., the
N370S mutation) are associated with type 1 GD, while severe
mutations (e.g., the L444P mutation) are associated with type
2 or type 3 GD. Some ethnicities show higher mutation rates;
Table 2 LRRK2-targeted treatments including LRRK2 inhibitors and antisense oligomeres under development for PD
LRRK2
Compound DNL201 DNL151 No public
data
No public data No public data BIIB094
Sponsor Denali Denali GSK Pfizer Genetech Biogen
RCT no. NCT03710707 NCT04056689 NCT03976349















completion end of 2022
Phase Phase 1b Phase 1b n/a n/a n/a Phase 1
Design Multicenter, randomized,
placebo-controlled




29 34 n/a n/a n/a 62
LRRK2-PD √ √ n/a n/a n/a √
Idiopathic
PD
√ √ n/a n/a n/a √
Age 30–75 n/a n/a n/a 35–80
Duration 28 days 28 days n/a n/a n/a n.d.
Doses tested Low/high Three doses n/a n/a n/a Single- and
multiple-ascending-dose
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specifically, in the Ashkenazi Jewish (AJ) population, the an-
nual incidence is 1/1000 and carrier frequencies are as high as
6% in all AJ. Both GD patients and healthy heterozygous
carriers are at increased risk for PD [52]. About 10% of
GBA mutation carriers will develop PD and studies suggest
that penetrance is age dependent [53]. As in LRRK2, there is
incomplete penetrance of PD among carriers and a wide range
of penetrance estimates.
Parkinsonism in GBA heterozygotes may be indistinguish-
able from iPD. However, they may have an earlier age at
onset, more prevalent cognitive impairment, and may not re-
spond to levodopa as well as iPD patients [54, 55]. GBA mu-
tations are also associated with other alpha-synucleinopathies,
including dementia with Lewy bodies [56] (pathologically
confirmed) and, in some studies, with MSA [57–61]. In con-
trast, there is no association with essential tremor or
Alzheimer’s disease.
Pathologically, the brains of patients with heterozygous
GBA mutations strongly resemble those from patients with
iPD. However, there is also widespread cortical Lewy body
involvement in GBA mutation carriers [55, 61]. A few studies
showed a reciprocal relationship between levels of
glucocerebrosidase (GCase; the enzyme encoded by GBA)
and levels of the aggregate-prone protein α-syn [62].
Notably, iPD patients also have reduced GCase activity (about
33% decrease) in the substantia nigra and cerebellum, making
treatments that target GBA relevant for iPD and patients with
PD dementia as well [11].
The GBA-encoded protein, glucocerebrosidase, is a lyso-
somal enzyme which plays a role in the breakdown of
glucocerebroside and glucosylsphingosine into glucose and
ceramide or sphingosine respectively. In GD, there is a lyso-
somal buildup of the substrate glucocerebroside in the
reticulo-endothelial system with reduced clearance. Gaucher
disease manifestations are a result of this diminished
glucocerebrosidase (GCase) activity. FDA-approved inter-
ventions for GD include enzyme replacement therapy (ERT)
and substrate reduction therapy (SRT), which are inhibitors of
the glucosylceramide synthase enzyme. None of the currently
approved drugs penetrate the blood–brain barrier, but theoret-
ically similar interventions that penetrate the blood–brain bar-
rier may modify the PD phenotype.
While the PD field can benefit from decades of GD re-
search, the underlying mechanisms of how GBA leads to the
development of PD are not fully understood. One hypothesis
is that there is a self-propagating bidirectional feedback loop
between GCase and α-syn. Loss of GCase activity causes α-
syn accumulation and oligomerization, resulting in neurotox-
icity through aggregate-dependent mechanisms [63].
Furthermore, elevated α-syn inhibits lysosomal maturation
and normal GCase activity while hindering GCase transport
from the endoplasmic reticulum to the lysosome. All of these
mechanisms continue over time until the threshold for
neurodegeneration is reached [63]. Based on this, targeted
treatments can take a variety of approaches including modu-
lation of glycosphingolipid turnover and restoration of en-
zyme function (Fig. 3, Table 3).
Treatment Directed at Modulation of Glycosphingolipid
Turnover
Substrate reduction therapy inhibits the biosynthesis of lipid
substrates and thereby prevents their accumulation. While this
approach does not target the mutant gene or dysfunctional
enzyme itself, it is an effective FDA-approved treatment of
the systemic symptoms of Gaucher disease. However, the
approved inhibitors show no effective CNS concentration
and do not affect the neurological symptoms of Gaucher dis-
ease (i.e., Gaucher type 2 and 3). New glucosylceramide syn-
thase inhibitors show good brain penetration, improved α-syn
processing, and behavioral outcomes in mouse models [43,
64]. Based on these findings, Sanofi launched the MOVES-
PD study, a randomized, double-blind, placebo-controlled tri-
al, in order to assess the efficacy and safety of the
glucosylceramide synthase inhibitor Venglustat (GZ/
SAR402671). Initial results from a phase I study were recently
published [65]. Briefly, 17 GBA-PD were enrolled (13 on
Venglustat, 4 on placebo; mean age 58 years, mean disease
duration 7 years) into this 36-week randomized, placebo-con-
trolled, double-blind, sequential cohort study of once-daily
Venglustat at three escalating doses. No serious adverse
events occurred. Side effects included psychological, neuro-
logical, and gastrointestinal-related symptoms. Plasma and
cerebrospinal fluid (CSF) glucosylceramide levels decreased
in a dose-dependent manner (up to 75%), confirming target
engagement. This favorable safety and tolerability profile of
Venglustat at all doses led the company to advance to a phase
II study (a 52-week trial which is currently ongoing) [65].
Treatment Directed at Restoration of Enzyme Function
Other therapies focus on the restoration of enzyme function, thus
increasing glucocerebrosidase activity, especially in the brain.
This can be achieved by [3)] ERT (enzyme replacement thera-
py), [9)] gene therapy, or [7)] small molecules. ERT is currently
available for patients with Gaucher disease. However, ERT is
based on large molecules and we are not familiar with any
clinical trials of ERT that may penetrate the blood–brain barrier.
Furthermore, there are no data on the use of ERT in PD.
Gene therapy uses adeno-associated virus vectors to deliver
engineeredDNA to human cells [43, 66]. ForGBA, preclinical
studies in mice demonstrated that adeno-associated virus-me-
diated expression of glucocerebrosidase corrected the aberrant
accumulation of the toxic lipid glucosylsphingosine and re-
duced the levels of ubiquitin, tau, and α-syn aggregates [67].
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started a gene therapy clinical trial of PR001 in 16 GBA-PD
patients in late 2019 (https://ir.prevailtherapeutics.com/news-
releases/news-release-details/prevail-therapeutics-provides-
program-update-pr001-parkinsons-0). The company will also
test the compound in children with neuropathic Gaucher
disease starting in the first half of 2020.
Furthermore, small molecules have also attracted attention
[68]. Early glucocerebrosidase chaperones that underwent
clinical trials for Gaucher disease included isofagomine
(afegostat-tartrate, AT2101). This treatment did not lead to
significant clinical improvement and further clinical develop-
ment for this indication was discontinued [43]. Ambroxol,
which is a promising small molecule chaperone widely used
in Europe as a mucolytic agent, may potentially facilitate the
transit of the misfolded GCase protein to the lysosome [69].
Its stabilizing and enhancing effects on the levels of GCase
were identified in a high-throughput screen in the context of
Gaucher disease [69]. It is pH dependent, binds to the active
site of the GCase protein, and reduces GCase activity.
Ambroxol has also been shown to improve lysosomal func-
tion and increase enzyme activity in in vitro studies utilizing
dermal fibroblasts with GBA mutations (i.e. [70] as well as in
studies performed on non-human primates (i.e. cynomolgus
monkeys) withGBAmutations [71]). The effects of Ambroxol
at high doses were recently tested in a single-center, open-
label, non-controlled, clinical trial (escalating oral dose to
1.26 g per day [420 mg 3 times per day] which is considerably
higher compared to the 30–120 mg/day used for the treatment
of respiratory disease) [72]. Eighteen patients with moderately
severe PD (mean age 60 years) completed the study, eight
with GBA mutations and ten mutation-negative. Ambroxol
penetrated CSF, but led to a 19% reduction from the mean
baseline CSF GCase activity at day 186. There was an in-
crease of CSF α-synuclein which the authors interpreted as
an increase of extracellular export of the protein from the brain
parenchyma. The drug was well tolerated, and no serious ad-
verse events were reported [72]. For other indications,
Ambroxol has been studied in > 15,000 patients in more than
100 trials with an excellent safety record [73]. As mentioned
above, GCase activity is also reduced in iPD patients’ brains
(SN) [74], making the therapy potentially relevant for iPD.
The effect of Ambroxol in non-GBA PD [75] and non-GBA
PD dementia [73] will be better understood once results from
the two ongoing studies become available. These studies in-
clude ten non-GBA PD and 75 PD dementia patients [73, 76]
(treated at daily doses of 420 mg/day or 525–1050 mg/day,
respectively).
The effects of LTI-291, an activator of the GCase enzyme
and another small molecule therapy, were studied in a 1-
month phase 1b trial conducted in the Netherlands, where
the frequency of GBA mutations was reported to be around
15% [48]. Around 40 GBA-PD patients participated. There
were no safety events and data showed a good dose-
dependent brain penetration (personal communication). The
company, Lysosomal Therapeutics, Inc. (LTI), is a
Massachusetts-based biotech venture which plans to develop
therapies for Gaucher disease and other lysosome-based neu-
rodegenerative diseases.
Small molecules can also modify GBA-PD by modifying
GBA-independent pathways. One such example is RTB101,
which is an inhibitor of the target of rapamycin complex 1
(TORC1) [77]. Rapamycin reached public attention when
Bloomberg magazine publicized it as a potential “forever pill”
in 2015. Known for its immunosuppressant properties,
rapamycin prolongs lifespan by 15–25% in various non-
mammalian organisms even when given late in life; it has also
been found to increase healthspan. A 5-year study in dogs is
planning on testing the geroprotective effects of RTB101 in
mammals [78]. TORC1 plays a role in cell growth and aging
and is the switch between fasting and feeding states [77].
Mutations in TORC1 cause focal cortical dysplasia, an
established cause of epilepsy. The role of mTORC1 in regu-
lating autophagy may also have implications for neurodegen-
erative diseases. In preclinical models, TORC1 inhibition in-
duces autophagy and prevents neuronal loss [79]. It improves
motor function in multiple PD models including α-syn
Fig. 3 Treatment approaches for GBA-associated PD include the modulation of glycosphingolipid turnover and restoration of enzyme function
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transgenic mice and MPTP models [80]. In oncology cell
cultures, treatment with RTB101 reduced the levels of
glucosylceramide, the main substrate of GCase. There is a
current phase 1b/2a trial of RTB101 in combination with
sirolimus that involves 45 PD patients with or without a
GBA mutation. The study was initiated in early 2019; data is
expected in 2020.
Deep Brain Stimulation for GBA-PD
Outcome data after DBS are available for around 30 GBA-PD
patients, 60% of whom showed a favorable response, whereas
30% showed a poor response [46]. However, sample sizes
remain small and genetic testing does not yet provide added
prognostic value over what can already be obtained through
careful clinical assessment when the patient is evaluated for
DBS surgery [81].
Targeting the Mitochondrial Pathways—Treatment
for PRKN/PINK1
The second major pathway implicated in PD pathogenesis is
mitochondrial metabolism, which is susceptible to damage by
oxidative stress. A prevailing hypothesis is that mutations in
PRKN and PINK1 cause PD due to mitochondrial dysfunc-
tion. Clinically, people with PRKN PD and PINK1 PD dis-
play an earlier-onset, are sensitive to levodopa, and are prone
to motor fluctuations. And, these patients have minimal cog-
nitive decline, even after many years of disease [13].
Hence, antioxidative strategies targeting Parkin (encoded
by PRKN) and PINK1-mediated mitophagy are another
emerging therapeutic approach for new treatments of PD.
Several small molecule drugs that enhance mitophagy are in
preclinical development and exploratory biomarkers for mito-
chondrial dysfunction and mitophagy activation are being
tested. However, there are many aspects that need to be con-
sidered such as selecting the most effective and feasible tar-
gets in the mitophagy pathway, potential side effects, and
stratification of the ideal population (for recent review, see
Miller and Muquit 2019 [82]).
It is important to note that several compounds targeting
mitochondria have been systematically studied in PD, includ-
ing coenzyme Q10 and creatine. However, these trials failed
to demonstrate a disease-modifying benefit in patients with
PD. Of these, coenzyme Q10 is currently revisited in a “small-
er, smarter trial” where patients are recruited based on their
genetic risk profile [83]. Hence, patients will be stratified ac-
cording to their risk for mitochondrial dysfunction (i.e.,
biallelic or monoallelic mutation in PRKN or PINK1 vs. pa-
tients in whom omics suggest little or minimal mitochondrial
dysfunction).
Challenges for Precision Clinical Trials
Surprisingly, the major challenge towards precision medicine
clinical trials for PD is not in the basic understanding of the
genes and their function, but rather in identifying mutation
carriers for clinical trials (Table 4). There are many ways
studies are trying to overcome this difficulty. In the case of
interventions targeting α-syn, the challenge in identifying car-
riers of point mutations or copy number variants has led to
clinical trials targeting patients with sporadic PD. In the case
of GBA and LRRK2, it is less clear whether interventions on
these pathways would help patients with sporadic PD. Given
the relative rarity of mutation carriers, GBA and LRRK2 trials
may include patients in different stages of PD, as opposed to
other clinical trials of disease modification which recruit pa-
tients in early PD who are often medication naïve. The inclu-
sion of patients at different stages of PD requires the develop-
ment of more sophisticated outcome measures that are less
sensitive to symptomatic, dopaminergic therapy than the stan-
dard motor examination, the Unified Parkinson’s Disease
Rating Scale (UPDRS).
The feasibility of genetically-targeted clinical trials would
require a significant change in the way genotyping is currently
practiced in PD. Only a small fraction of PD patients are
clinically genotyped in CLIA-approved laboratories and know
their genetic status [85]. A few pharmaceutical companies
launched major genotyping efforts, e.g., Denali Therapeutics
in collaboration with Centogene (https://www.centogene.
com/company/article/centogene-and-denali-therapeutics-
Table 4 Top four challenges and
barriers to effective clinical trials
as perceived by health
professionals, patients, and their
caregivers—for the full list, see
Mathur et al. (2015) [84]
Scientists and other health professionals Patients and caregivers
Lack of funding Risk of potential adverse consequences and potential
side effects
Lack of administrative support and time available to
manage the trial
Disruption to normal medication regimen
Slow and difficult recruitment of people Prospect of receiving a placebo instead of the active
drug
Lack of practical support Upheaval and inconvenience to life that trial
participation would cause
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announce-strategic-collaboration-to-recruit-lrrk2-patients-for-
cli.html [online]). In this context, the Parkinson’s Foundation
launched the PD GENEration initiative (currently conducted
at 6 sites in the USA), which offers free genetic testing for
clinically relevant PD-related genes and free genetic counsel-
ing to help participants better understand their results. More
about current efforts in “Overcoming barriers to PD trial par-
ticipation” are discussed in chapter 15 of this special issue.
Another major challenge is the identification of reliable and
validated disease markers and outcome measurements that are
suitable for targeted intervention. Past trials largely relied on
clinical motor impressions (e.g. UPDRS in the “off” state
during clinic visits) which may not robustly detect disease-
modifying effects. Better biomarkers are needed to evaluate
the effectiveness of treatments by reflecting drug target en-
gagement, disease severity, and progression of disease.
Having a reliable marker would enhance drug development.
For example, in the case of Huntington’s disease, trials now
include femtomolar-sensitive quantification (single molecule
counting immunoassay) of the mutant protein in CSF [86].
For PD, Real-Time Quaking-Induced Conversion (RT-
QuIC) techniques are being tested to determine their sensitiv-
ity and specificity [87]. There is also still a lack of reliable α-
syn imaging methods which is a barrier to testing promising
compounds; however, targeting a-syn is a major pursuit on the
research front [88, 89]. Using artificial intelligence may ad-
vance the field further by identifying new biomarkers or facil-
itating biomarker validation and application.
Furthermore, better understanding of disease mechanisms
linking these genes to PD is necessary. In LRRK2 and SNCA,
while detailed mechanisms are not fully understood, treat-
ments are focused on reducing activity or expression. In the
case of GBA, as outlined above, enhancing or restoring en-
zyme function are currently favored approaches. Drug devel-
opment for other genetic forms lags behind (e.g., PRKN),
because suitable druggable targets have not been identified.
Concerted efforts are being made to identify a variety of dis-
ease progression markers including biospecimen-based (i.e.,
blood, urine, CSF or biopsy; molecular, genomic, cellular),
clinical, imaging, or others (e.g., electrophyiological, behav-
ioral, and environmental). Among these, the PPMI initiative is
a valuable source that brings together longitudinal data and
specimen collection from more than 1200 volunteers with PD
[15].
Summary and Final Remarks
Recent failures in large Phase III clinical trials for PD suggest
that disease modification will not succeed as long as PD is
treated as a single disease with one pathophysiology.
Therefore, we believe that precision medicine in PD may be
a promising alternative and a timely approach.
As summarized in this review, several gene-based therapies
are being tested in clinical trials and numerous more are in the
pipeline. These are exciting times. However, the process of
bringing a drug into the clinic is cumbersome [90].
Pharmaceutical Research and Manufacturers of America
(PhRMA) estimate that for every 5000 to 10,000 compounds
screened, only five enter human clinical trials, only one is
approved by the Food and Drug Administration, and only
two in ten drugs generate enough revenue to recoup their
research and development costs [91]. Thus, setbacks are
expected.
One unanswered question is whowill benefit from new “pre-
cision” drugs. Will these be useful only for mutation carriers
(and therefore require an orphan drug assignment) or will they
be beneficial for the larger group of idiopathic PD or atypical
parkinsonian disorders? It seems unlikely that these broad
groups will all respond to the same drug unless there are shared
downstream disease mechanisms. One may even have to differ-
entiate among mutations withinGBA due to the effect a specific
mutation has on the protein. For example, the affinity of chap-
erones to a mutated enzyme may be different depending on the
mutation. Furthermore, a new drug that facilitates protein func-
tion may fail in patients with null mutations who do not express
any protein. The term “super precision medicine” has been used
to capture this phenomenon. To be able to make the most out of
clinical trial data, future clinical trials will benefit from pretrial
genetic adjustment or, at the minimum, post-trial adjustment,
and analysis for failed trials [92].
However, in addition to addressing the purely scientific
aspects, success in drug development also depends on funding
opportunities for late preclinical development phases which
are significantly more expensive than early-stage discovery.
Experience shows that promising ideas have often failed in
this “Valley of Death” (a term coined by former NIH director,
Elias Zerhouni) [93]. Feasible regulatory frameworks and ef-
ficient data-sharing ecosystems [94] that also ensure ethical
leadership and governance [95] as well as new funding instru-
ments (for example, similar to the recently initated public-
private partnership set up to boost research and drug develop-
ment in infectious diseases and thereby to address market
failures [84]) will facilitate drug development.
Raising awareness and educating the community, includ-
ing physicians, patients, and caregivers, will be an important
step towards successful future studies [85]. Advancing preci-
sion medicine will not only shift current reactive approaches
to proactive detection and prevention, but will also help the
next generation of scientists develop creative new approaches
for detecting, measuring, and treating Parkinson’s disease.
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